Analyst consensus rating
Kalaris Therapeutics Analyst Rating: Strong Buy
Direct answer
Kalaris Therapeutics's consensus rating is Strong Buy.
6 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $16.33.
Forecast evidence checked November 21, 2026.
Get free Kalaris Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $1.28
- Average price target
- $16.33
- High price target
- $23.00
- Low price target
- $4.00
- Low target gap
- +212.5%
- Target upside
- +1,176%
- High target gap
- +1,696.9%
- Target range width
- 1,484.4%
- Consensus rating
- Strong Buy
- Analysts
- 6
- Evidence date
- November 21, 2026
- Valid through
- November 28, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Kalaris Therapeutics?
Kalaris Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $16.33.
How far are Kalaris Therapeutics's low and high targets from the recorded price?
The low target implies +212.5%, while the high target implies +1,696.9%.
How many analysts are included in Kalaris Therapeutics's consensus?
The verified consensus includes 6 analysts.
How is Kalaris Therapeutics's target upside or downside calculated?
The average target of $16.33 is divided by the recorded price of $1.28, then one is subtracted to produce +1,176%. This does not guarantee a future return.
When was Kalaris Therapeutics's analyst forecast verified?
The data was verified on 2026-11-21. The dataset is valid through 2026-11-28.